Los Angeles Capital Management LLC Has $3.84 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Los Angeles Capital Management LLC raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,918 shares of the company’s stock after buying an additional 163 shares during the period. Los Angeles Capital Management LLC’s holdings in IDEXX Laboratories were worth $3,840,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Patron Partners LLC lifted its position in IDEXX Laboratories by 2.7% during the 4th quarter. Patron Partners LLC now owns 765 shares of the company’s stock worth $425,000 after buying an additional 20 shares in the last quarter. NewEdge Wealth LLC lifted its position in shares of IDEXX Laboratories by 3.1% during the fourth quarter. NewEdge Wealth LLC now owns 659 shares of the company’s stock worth $366,000 after purchasing an additional 20 shares in the last quarter. Phoenix Holdings Ltd. lifted its position in shares of IDEXX Laboratories by 2.8% during the third quarter. Phoenix Holdings Ltd. now owns 769 shares of the company’s stock worth $338,000 after purchasing an additional 21 shares in the last quarter. BluePath Capital Management LLC grew its stake in shares of IDEXX Laboratories by 1.8% during the fourth quarter. BluePath Capital Management LLC now owns 1,197 shares of the company’s stock valued at $663,000 after purchasing an additional 21 shares during the last quarter. Finally, Valley National Advisers Inc. increased its holdings in shares of IDEXX Laboratories by 84.6% in the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Up 1.0 %

Shares of NASDAQ IDXX opened at $480.60 on Monday. The firm has a 50 day moving average price of $523.29 and a two-hundred day moving average price of $513.58. The stock has a market cap of $39.69 billion, a P/E ratio of 46.52, a price-to-earnings-growth ratio of 3.78 and a beta of 1.27. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The business had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. During the same period in the prior year, the business posted $2.05 earnings per share. IDEXX Laboratories’s quarterly revenue was up 8.8% on a year-over-year basis. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.05 EPS for the current year.

Insider Buying and Selling

In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the transaction, the chief executive officer now owns 79,247 shares of the company’s stock, valued at approximately $45,377,624.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other IDEXX Laboratories news, CFO Brian P. Mckeon sold 23,326 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the sale, the chief financial officer now owns 29,718 shares in the company, valued at approximately $16,939,557.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the transaction, the chief executive officer now owns 79,247 shares in the company, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. Insiders sold 43,524 shares of company stock valued at $24,871,960 over the last 90 days. Company insiders own 2.18% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research reports. Barclays cut their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. JPMorgan Chase & Co. lifted their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price for the company. in a report on Tuesday, January 30th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $580.88.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.